MedDataX Logo

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT ID: NCT05139017

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-14

Study Completion Date

2027-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR.

With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DLBCL Diffuse Large B-Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

In Part 1, Dose Confirmation will be determined by modified toxicity probability interval (mTPI) design, where participants will be assigned to two treatment groups, cohort: A (zilovertamab vedotin in combinatio with R-GemOx) in parallel with cohort B (zilovertamab vedotin in combination with BR). Part 2 will be an Efficacy Expansion (cohorts A \& B) where all participants in each cohort will be assigned to 2 treatment groups for the duration of the study.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZV + R-GemOx (Part 1)

Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.

Group Type EXPERIMENTAL

Zilovertamab vedotin

Intervention Type BIOLOGICAL

Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Gemcitabine

Intervention Type DRUG

IV Infusion 1000 mg/m\^2

Oxaliplatin

Intervention Type DRUG

IV Infusion 100 mg/m\^2

Granulocyte Colony-Stimulating Factor (G-CSF)

Intervention Type DRUG

Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

ZV + R-GemOx (Part 2)

Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.

Group Type EXPERIMENTAL

Zilovertamab vedotin

Intervention Type BIOLOGICAL

Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Gemcitabine

Intervention Type DRUG

IV Infusion 1000 mg/m\^2

Oxaliplatin

Intervention Type DRUG

IV Infusion 100 mg/m\^2

Granulocyte Colony-Stimulating Factor (G-CSF)

Intervention Type DRUG

Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

R-GemOx (active control for Part 2)

Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Gemcitabine

Intervention Type DRUG

IV Infusion 1000 mg/m\^2

Oxaliplatin

Intervention Type DRUG

IV Infusion 100 mg/m\^2

ZV + BR (Part 2)

Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.

Group Type EXPERIMENTAL

Zilovertamab vedotin

Intervention Type BIOLOGICAL

Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Bendamustine

Intervention Type DRUG

IV Infusion 90 mg/m\^2

Granulocyte Colony-Stimulating Factor (G-CSF)

Intervention Type DRUG

Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

Bendamustine Rituximab (BR)

Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Bendamustine

Intervention Type DRUG

IV Infusion 90 mg/m\^2

ZV + BR (Part 1)

Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.

Group Type EXPERIMENTAL

Zilovertamab vedotin

Intervention Type BIOLOGICAL

Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Rituximab

Intervention Type BIOLOGICAL

IV Infusion 375 mg/m\^2

Bendamustine

Intervention Type DRUG

IV Infusion 90 mg/m\^2

Granulocyte Colony-Stimulating Factor (G-CSF)

Intervention Type DRUG

Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zilovertamab vedotin

Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

Intervention Type BIOLOGICAL

Rituximab

IV Infusion 375 mg/m\^2

Intervention Type BIOLOGICAL

Gemcitabine

IV Infusion 1000 mg/m\^2

Intervention Type DRUG

Oxaliplatin

IV Infusion 100 mg/m\^2

Intervention Type DRUG

Bendamustine

IV Infusion 90 mg/m\^2

Intervention Type DRUG

Granulocyte Colony-Stimulating Factor (G-CSF)

Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-2140 VLS-101 Rituxan®/mabthera Truxima® (rituximab-abbs) RUXIENCE®, RIABNI® Gemzar® Eloxatin® Bendeka® Treanda® Belrapzo®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL).
* Has radiographically measurable DLBCL per the Lugano Response Criteria, as assessed locally by the investigator.
* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 within 7 days prior to study treatment initiation.
* Has adequate organ function.
* Is able to provide new or archival tumor tissue sample not previously irradiated.

Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms:

* Has relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least 1 line of prior therapy.
* Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or is ineligible for CAR-T cell therapy.

Not applicable with protocol amendment 4: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms:

* Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least 2 lines of prior therapy.
* Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy.

Exclusion Criteria

* Not applicable with protocol amendment 4: Has history of transformation of indolent disease to DLBCL
* Has received solid organ transplant at any time.
* Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL).
* Has clinically significant (ie, active) cardiovascular disease or serious cardiac arrhythmia requiring medication.
* Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatment for their GVHD.
* Has clinically significant pericardial or pleural effusion.
* Has ongoing Grade \>1 peripheral neuropathy.
* Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
* Has a demyelinating form of Charcot-Marie-Tooth disease.
* Has contraindication to any of the study intervention components including but not limited to prior anaphylactic reaction.
* Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention.
* Has received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
* Has ongoing corticosteroid therapy.
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
* Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission.
* Has an active infection requiring systemic therapy.
* Has a known history of human immunodeficiency virus (HIV) infection.
* Has a known active Hepatitis C virus infection.
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bass Medical Group ( Site 0166)

Walnut Creek, California, United States

Site Status RECRUITING

Innovative Clinical Research Institute ( Site 0122)

Whittier, California, United States

Site Status COMPLETED

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)

Boca Raton, Florida, United States

Site Status RECRUITING

Clermont Oncology Center ( Site 0174)

Clermont, Florida, United States

Site Status RECRUITING

Saint Elizabeth Medical Center Edgewood ( Site 0165)

Edgewood, Kentucky, United States

Site Status RECRUITING

University of Kentucky Chandler Medical Center ( Site 0158)

Lexington, Kentucky, United States

Site Status RECRUITING

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)

Louisville, Kentucky, United States

Site Status RECRUITING

University of Maryland ( Site 0123)

Baltimore, Maryland, United States

Site Status RECRUITING

Dana-Farber Cancer Institute-Lymphoma ( Site 0111)

Boston, Massachusetts, United States

Site Status RECRUITING

University of Massachusetts Medical School ( Site 0119)

Worcester, Massachusetts, United States

Site Status RECRUITING

St. Vincent Frontier Cancer Center-Research ( Site 0108)

Billings, Montana, United States

Site Status RECRUITING

Comprehensive Cancer Centers of Nevada ( Site 0168)

Las Vegas, Nevada, United States

Site Status RECRUITING

Atlantic Health System ( Site 0116)

Morristown, New Jersey, United States

Site Status RECRUITING

New York Medical College ( Site 0113)

Valhalla, New York, United States

Site Status RECRUITING

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156)

Nashville, Tennessee, United States

Site Status COMPLETED

Blue Ridge Cancer Care ( Site 0169)

Roanoke, Virginia, United States

Site Status RECRUITING

Hospital Italiano de Buenos Aires ( Site 2203)

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status RECRUITING

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205)

Mar del Plata, Buenos Aires, Argentina

Site Status RECRUITING

Hospital Aleman ( Site 2200)

Buenos Aites, Buenos Aires F.D., Argentina

Site Status RECRUITING

Hospital Privado Universitario de Córdoba ( Site 2202)

Córdoba, Córdoba Province, Argentina

Site Status RECRUITING

Instituto Alexander Fleming ( Site 2201)

CABA, , Argentina

Site Status RECRUITING

Townsville University Hospital ( Site 1800)

Douglas, Queensland, Australia

Site Status RECRUITING

Grampians Health ( Site 1802)

Ballarat, Victoria, Australia

Site Status RECRUITING

Royal Perth Hospital-Haematology ( Site 1801)

Perth, Western Australia, Australia

Site Status RECRUITING

Hospital Erasto Gaertner ( Site 2302)

Curitiba, Paraná, Brazil

Site Status RECRUITING

Liga Norte Riograndense Contra o Câncer ( Site 2305)

Natal, Rio Grande do Norte, Brazil

Site Status RECRUITING

Hospital Paulistano ( Site 2300)

São Paulo, , Brazil

Site Status RECRUITING

Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306)

São Paulo, , Brazil

Site Status RECRUITING

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)

Toronto, Ontario, Canada

Site Status COMPLETED

IC La Serena Research ( Site 2405)

La Serena, Coquimbo Region, Chile

Site Status RECRUITING

Oncocentro Valdivia ( Site 2407)

Valdivia, Los Ríos Region, Chile

Site Status RECRUITING

FALP-UIDO ( Site 2400)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Clínica Inmunocel ( Site 2404)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Clínica RedSalud Vitacura ( Site 2409)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Bradfordhill ( Site 2403)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Biocenter ( Site 2401)

Concepción, Región del Biobío, Chile

Site Status RECRUITING

Beijing Cancer hospital ( Site 3000)

Beijing, Beijing Municipality, China

Site Status RECRUITING

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025)

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Chongqing University Three Gorges Hospital ( Site 3026)

Chongqing, Chongqing Municipality, China

Site Status ACTIVE_NOT_RECRUITING

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001)

Guangzhou, Guangdong, China

Site Status RECRUITING

Zhujiang Hospital ( Site 3002)

Guangzhou, Guangdong, China

Site Status RECRUITING

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029)

Luoyang, Henan, China

Site Status RECRUITING

Henan Cancer Hospital-hematology department ( Site 3013)

Zhengzhou, Henan, China

Site Status RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017)

Wuhan, Hubei, China

Site Status RECRUITING

The First Affiliated Hospital of Nanchang University ( Site 3004)

Nanchang, Jiangxi, China

Site Status RECRUITING

Jiangxi Provincial Cancer Hospital ( Site 3005)

Nanchang, Jiangxi, China

Site Status RECRUITING

The First Hospital of Jilin University-Hematology ( Site 3012)

Changchun, Jilin, China

Site Status RECRUITING

Fudan University Shanghai Cancer Center ( Site 3009)

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016)

Chengdu, Sichuan, China

Site Status RECRUITING

Sichuan Cancer hospital-Oncology ( Site 3021)

Chengdu, Sichuan, China

Site Status RECRUITING

Zhejiang Cancer Hospital ( Site 3014)

Hangzhou, Zhejiang, China

Site Status RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027)

Hangzhou, Zhejiang, China

Site Status RECRUITING

Hospital Pablo Tobon Uribe ( Site 0804)

Medellín, Antioquia, Colombia

Site Status RECRUITING

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801)

Bogotá, Bogota D.C., Colombia

Site Status RECRUITING

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803)

Montería, Departamento de Córdoba, Colombia

Site Status RECRUITING

Oncologos del Occidente ( Site 0800)

Pereira, Risaralda Department, Colombia

Site Status RECRUITING

Fundacion Valle del Lili ( Site 0802)

Cali, Valle del Cauca Department, Colombia

Site Status RECRUITING

Hospital Metropolitano - Sede Lindora ( Site 2500)

Santa Ana, Provincia de San José, Costa Rica

Site Status RECRUITING

CIMCA ( Site 2501)

San José, , Costa Rica

Site Status RECRUITING

centre hospitalier lyon sud-Service Hématologie ( Site 0702)

Pierre-Bénite, Rhone, France

Site Status ACTIVE_NOT_RECRUITING

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700)

Paris, , France

Site Status RECRUITING

Evangelismos General Hospital of Athens ( Site 0900)

Athens, Attica, Greece

Site Status RECRUITING

Regional General Hospital of Athens "Laiko" ( Site 0901)

Athens, Attica, Greece

Site Status RECRUITING

University Hospital of Alexandroupolis ( Site 0903)

Alexandroupoli, East Macedonia and Thrace, Greece

Site Status RECRUITING

MEDI-K ( Site 2602)

Guatemala City, , Guatemala

Site Status RECRUITING

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601)

Guatemala City, , Guatemala

Site Status RECRUITING

CELAN,S.A ( Site 2603)

Guatemala City, , Guatemala

Site Status RECRUITING

Queen Mary Hospital ( Site 3100)

Hong Kong, , Hong Kong

Site Status RECRUITING

Princess Margaret Hospital ( Site 3101)

Hong Kong, , Hong Kong

Site Status RECRUITING

Emek Medical Center-Hematology Unit ( Site 1102)

Afula, , Israel

Site Status COMPLETED

Carmel Hospital ( Site 1103)

Haifa, , Israel

Site Status COMPLETED

Hadassah Medical Center ( Site 1100)

Jerusalem, , Israel

Site Status COMPLETED

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203)

Rozzano, Milano, Italy

Site Status RECRUITING

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200)

Bologna, , Italy

Site Status COMPLETED

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202)

Napoli, , Italy

Site Status RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204)

Roma, , Italy

Site Status COMPLETED

Health Pharma Professional Research S.A. de C.V: ( Site 2700)

Mexico City, Mexico City, Mexico

Site Status RECRUITING

Medivest Centro de Investigación Integral ( Site 2704)

Chihuahua City, , Mexico

Site Status RECRUITING

Centro de Infusion Superare ( Site 2701)

Mexico City, , Mexico

Site Status RECRUITING

Aotearoa Clinical Trials ( Site 0501)

Auckland, , New Zealand

Site Status RECRUITING

Clínicas AUNA Sede Chiclayo ( Site 2803)

Chiclayo, Lambayeque, Peru

Site Status RECRUITING

Clínica San Felipe ( Site 2805)

Lima, , Peru

Site Status RECRUITING

Hospital Nacional Edgardo Rebagliati Martins ( Site 2802)

Lima, , Peru

Site Status RECRUITING

Hospital Nacional Dos De Mayo ( Site 2804)

Lima, , Peru

Site Status RECRUITING

Pratia MCM Krakow ( Site 1303)

Krakow, Lesser Poland Voivodeship, Poland

Site Status RECRUITING

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305)

Wałbrzych, Lower Silesian Voivodeship, Poland

Site Status RECRUITING

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301)

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status COMPLETED

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304)

Lublin, Lublin Voivodeship, Poland

Site Status COMPLETED

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300)

Warsaw, Masovian Voivodeship, Poland

Site Status RECRUITING

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302)

Gdynia, Pomeranian Voivodeship, Poland

Site Status COMPLETED

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309)

Słupsk, Pomeranian Voivodeship, Poland

Site Status RECRUITING

Pratia Onkologia Katowice ( Site 1306)

Katowice, Silesian Voivodeship, Poland

Site Status RECRUITING

Seoul National University Hospital-Oncology ( Site 0302)

Seoul, , South Korea

Site Status RECRUITING

Samsung Medical Center ( Site 0300)

Seoul, , South Korea

Site Status RECRUITING

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400)

Bangkok, Bangkok, Thailand

Site Status ACTIVE_NOT_RECRUITING

Chulalongkorn University ( Site 0402)

Pathumwan, Bangkok, Thailand

Site Status ACTIVE_NOT_RECRUITING

Maharaj Nakorn Chiang Mai Hospital ( Site 0401)

Chiang Mai, , Thailand

Site Status ACTIVE_NOT_RECRUITING

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912)

Yenimahalle, Ankara, Turkey (Türkiye)

Site Status RECRUITING

Ege University Medicine of Faculty ( Site 1902)

Bornova, İzmir, Turkey (Türkiye)

Site Status RECRUITING

Ankara University Hospital Cebeci-hematology ( Site 1901)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Mega Medipol-Hematology ( Site 1909)

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Dokuz Eylül Üniversitesi-Hematology ( Site 1905)

Izmir, , Turkey (Türkiye)

Site Status RECRUITING

Ondokuz Mayıs Universitesi ( Site 1907)

Samsun, , Turkey (Türkiye)

Site Status COMPLETED

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000)

Cherkasy, Cherkasy Oblast, Ukraine

Site Status RECRUITING

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004)

Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

Site Status RECRUITING

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002)

Lviv, Lviv Oblast, Ukraine

Site Status RECRUITING

State non-profit enterprise National Cancer Institute ( Site 2001)

Kyiv, , Ukraine

Site Status RECRUITING

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005)

Kyiv, , Ukraine

Site Status RECRUITING

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003)

Kyiv, , Ukraine

Site Status RECRUITING

Aberdeen Royal Infirmary ( Site 2104)

Aberdeen, Aberdeen City, United Kingdom

Site Status RECRUITING

The Royal Cornwall Hospital ( Site 2103)

Truro, England, United Kingdom

Site Status RECRUITING

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100)

London-Camden, London, City of, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Canada Chile China Colombia Costa Rica France Greece Guatemala Hong Kong Israel Italy Mexico New Zealand Peru Poland South Korea Thailand Turkey (Türkiye) Ukraine United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Toll Free Number

Role: CONTACT

Phone: 1-888-577-8839

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://www.merckclinicaltrials.com/

Merck Clinical Trials Information

https://msd.trialsummaries.com/Study/StudyDetails?id=26287&tenant=MT_MSD_9011

Plain Language Summary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VLS-101

Identifier Type: OTHER

Identifier Source: secondary_id

MK-2140-003

Identifier Type: OTHER

Identifier Source: secondary_id

waveLINE-003

Identifier Type: OTHER

Identifier Source: secondary_id

2022-502646-27-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1285-0898

Identifier Type: REGISTRY

Identifier Source: secondary_id

2140-003

Identifier Type: -

Identifier Source: org_study_id